-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 24, 2021, a study published by "Nature" IL-27 signaling promotes adipocyte thermogenesis and energy expenditure pointed out that interleukin 27 (IL-27) can directly target and promote the browning and thermogenesis of fat cells.
, By burning lipids to reduce obesity and improve type 2 diabetes
.
The research results bring new hope for the treatment of obesity and type 2 diabetes
.
According to the WHO epidemiological survey, in 2016, more than 1.
9 billion adults over the age of 18 were overweight (body mass index-BMI ≥ 25, accounting for 39% of the adult population), and more than 650 million of them were obese (body mass index) -BMI≥30, accounting for 13%), the prevalence has increased nearly three times compared with 1975
.
This greatly increases the risk of developing non-communicable diseases such as cardiovascular disease, diabetes, osteoarthritis and cancer
.
The root cause of obesity is that calorie intake exceeds consumption, which causes energy to accumulate in fat cells in the form of lipids, and immune cells are deeply involved in this process; however, immune cells and factors are complex and diverse in the process of obesity, which regulates the process of obesity The role needs to be analyzed in depth
.
The team of Professor Yin Zhinan of Jinan University found that the level of IL-27 in the serum of obese people was significantly down-regulated
.
By constructing a variety of genetically engineered mice and carrying out an obesity model induced by a high-fat diet, the authors discovered for the first time that IL-27 directly acts on fat cells, causing white fat cells to brown, and activating UCP1-mediated "fat burning".
The lipids in adipose tissue are converted into calories and consumed, thereby achieving the effect of reducing body weight and improving metabolic diseases such as diabetes
.
This breaks through the traditional idea that IL-27 specifically targets immune cells
.
In animal experiments, injection of recombinant IL-27 can significantly reduce the weight of obese mice and improve insulin signal sensitivity, which preliminarily verifies the potential of IL-27 as a therapeutic drug
.
IL-27 can promote heat production and energy consumption
.
The author pointed out that this study provides new targets and potential drugs for the treatment of obesity and related metabolic diseases.
IL-27, as an immune molecule normally expressed in the body, has good safety and therefore has huge clinical applications.
Potential and market value
.
Professor Yin Zhinan’s team is very much looking forward to the industrialization of this therapeutic target as soon as possible, hoping that the results can benefit the majority of obese people
.
©NatureNature | doi: 10.
1038/s41586-021-04127-5
, By burning lipids to reduce obesity and improve type 2 diabetes
.
The research results bring new hope for the treatment of obesity and type 2 diabetes
.
According to the WHO epidemiological survey, in 2016, more than 1.
9 billion adults over the age of 18 were overweight (body mass index-BMI ≥ 25, accounting for 39% of the adult population), and more than 650 million of them were obese (body mass index) -BMI≥30, accounting for 13%), the prevalence has increased nearly three times compared with 1975
.
This greatly increases the risk of developing non-communicable diseases such as cardiovascular disease, diabetes, osteoarthritis and cancer
.
The root cause of obesity is that calorie intake exceeds consumption, which causes energy to accumulate in fat cells in the form of lipids, and immune cells are deeply involved in this process; however, immune cells and factors are complex and diverse in the process of obesity, which regulates the process of obesity The role needs to be analyzed in depth
.
The team of Professor Yin Zhinan of Jinan University found that the level of IL-27 in the serum of obese people was significantly down-regulated
.
By constructing a variety of genetically engineered mice and carrying out an obesity model induced by a high-fat diet, the authors discovered for the first time that IL-27 directly acts on fat cells, causing white fat cells to brown, and activating UCP1-mediated "fat burning".
The lipids in adipose tissue are converted into calories and consumed, thereby achieving the effect of reducing body weight and improving metabolic diseases such as diabetes
.
This breaks through the traditional idea that IL-27 specifically targets immune cells
.
In animal experiments, injection of recombinant IL-27 can significantly reduce the weight of obese mice and improve insulin signal sensitivity, which preliminarily verifies the potential of IL-27 as a therapeutic drug
.
IL-27 can promote heat production and energy consumption
.
The author pointed out that this study provides new targets and potential drugs for the treatment of obesity and related metabolic diseases.
IL-27, as an immune molecule normally expressed in the body, has good safety and therefore has huge clinical applications.
Potential and market value
.
Professor Yin Zhinan’s team is very much looking forward to the industrialization of this therapeutic target as soon as possible, hoping that the results can benefit the majority of obese people
.
©NatureNature | doi: 10.
1038/s41586-021-04127-5
